Olema Pharmaceuticals OLMA 深 沪
已收盘 10-24 16:00:00 美东时间
8.03
-0.060
-0.74%
华盛通- 最 高8.33
- 今 开8.25
- 成交量 113.70万股
- 最 低 7.94
- 昨 收 8.09
- 总市值 5.51亿
- 52周最高 13.51
- 市盈率 静 --
- 换手率 1.66%
- 52周最低 2.86
- 委 比 58.60%
- 总股本 6863.43万
- 历史最高 60.27
- 量 比 0.50
- 振 幅 4.82%
- 历史最低 2.00
- 每 手 1
- 风险率 2.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Olema falls 30% on data for breast cancer candidate palazestrant
Olema Pharmaceuticals (NASDAQ:OLMA) plunged 30% in pre-market trading Monday after announcing new data from a phase 1b/2 trial of palazestrant in breast cancer. The candidate is under investigation in...
10-20 21:16
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) stock increased by 95.3% to $8.79 during...
10-20 20:08
Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceut...
10-20 06:55
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Olema Pharmaceuticals announced positive updated data from a Phase 1b/2 study of palazestrant in combination with ribociclib for ER+/HER2- advanced or metastatic breast cancer. The combination showed encouraging efficacy across all dose cohorts, with median PFS of 15.5 months for all patients in the 120 mg palazestrant cohort. Among patients with prior CDK4/6i treatment, median PFS was 9.2 months for ESR1 wild-type tumors and 13.8 months for ESR1...
10-18 07:00
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
The outlook for the KAT6 inhibitors market is strengthening as interest in epig...
09-17 05:31
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Pfizer collaboration with Olema may spark future bidding war - analyst
Olema Pharmaceutical's (NASDAQ:OLMA) announcement of a new clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) in metastatic breast cancer may be a sign of a potential bidding war...
09-04 03:26
